collection
MENU ▼
Read by QxMD icon Read
search

Pof

shared collection
9 papers 0 to 25 followers
By Su Ling Yu Obgyn interested in reproductive medicine
https://www.readbyqxmd.com/read/28365199/outcomes-of-immature-oocytes-collected-from-ovarian-tissue-for-cryopreservation-in-adult-and-prepubertal-patients
#1
Giovanna Fasano, Julie Dechène, Raffaella Antonacci, Jamila Biramane, Anne-Sophie Vannin, Anne Van Langendonckt, Fabienne Devreker, Isabelle Demeestere
The efficiency of oocyte in-vitro maturation (IVM) and vitrification procedures after ex-vivo collection from ovarian tissue were assessed according to patient age, number of retrieved oocytes and tissue transport conditions. The combined procedure was performed in 136 patients: 130 adults (mean 27.6 ± 5.6 years) and six prepubertal girls (mean 8.7 ± 2.3 years). A higher mean number of oocytes were collected in girls compared with adults (11.5 ± 8.0 versus 3.8 ± 4.2, respectively, P < 0.001) but the percentage of degenerated oocytes was significantly higher in girls (35...
March 20, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/23835721/fifteen-year-follow-up-of-embryos-cryopreserved-in-cancer-patients-for-fertility-preservation
#2
J Barcroft, N Dayoub, K J Thong
PURPOSE: Determine the outcome of embryo cryopreservation in female oncology patients METHODS: The outcomes of IVF/ICSI cycles in oncology patients over 15 years in a University Teaching Hospital. RESULTS: Forty-two oncology patients (mean 31.9 ± 3.9 years) underwent embryo cryopreservation treatment (n = 33 IVF, n = 6 ICSI). Controlled ovarian stimulation with GnRH antagonist protocol (n = 34; 81 %) yielded fewer oocytes than GnRH agonist protocol (n = 8; 19 %) (9...
November 2013: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/26347105/ovarian-suppression-using-luteinizing-hormone-releasing-hormone-agonists-during-chemotherapy-to-preserve-ovarian-function-and-fertility-of-breast-cancer-patients-a-meta-analysis-of-randomized-studies
#3
REVIEW
M Lambertini, M Ceppi, F Poggio, F A Peccatori, H A Azim, D Ugolini, P Pronzato, S Loibl, H C F Moore, A H Partridge, P Bruzzi, L Del Mastro
BACKGROUND: The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature ovarian failure (POF) is still controversial. Our meta-analysis of randomized, controlled trials (RCTs) investigates whether the use of LHRHa during chemotherapy in premenopausal breast cancer patients reduces treatment-related POF rate, increases pregnancy rate, and impacts disease-free survival (DFS). METHODS: A literature search using PubMed, Embase, and the Cochrane Library, and the proceedings of major conferences, was conducted up to 30 April 2015...
December 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26957619/fertility-preservation-in-patients-with-breast-cancer-necessity-methods-and-safety
#4
REVIEW
Adrienne G Waks, Ann H Partridge
As treatment paradigms improve and young women live longer after a breast cancer diagnosis, there is an increasing need to define the fertility-related problems that premenopausal women with breast cancer face, and, more importantly, to find solutions. This article discusses what is known regarding fertility risks associated with standard breast cancer treatment regimens and limitations of that information. We outline established and emerging techniques for fertility preservation, including recent developments surrounding the controversial utility of gonadotropin-releasing hormone agonists through chemotherapy, and review available data on the safety of pregnancy in breast cancer survivors...
March 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27644002/controversies-over-the-use-of-gnrh-agonists-for-reduction-of-chemotherapy-induced-gonadotoxicity
#5
EDITORIAL
M F Garrido-Oyarzún, C Castelo-Branco
The increase in cancer incidence in younger people and the significant improvement in long and permanent remission have brought concern about their reproductive future and quality of life. Up to two-thirds of adult female patients undergoing chemotherapy for malignancies eventually develop premature ovarian failure. This condition is related to many complaints including vasomotor symptoms, osteoporosis, increased risk of cardiovascular diseases, sexual dysfunction, and infertility. Therefore, protection against iatrogenic infertility and loss of endocrine ovarian function caused by chemotherapy is currently of high priority...
December 2016: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/26426573/gonadotropin-releasing-hormone-agonists-for-ovarian-function-preservation-in-premenopausal-women-undergoing-chemotherapy-for-early-stage-breast-cancer-a-systematic-review-and-meta-analysis
#6
REVIEW
Rodrigo R Munhoz, Allan A L Pereira, André D Sasse, Paulo M Hoff, Tiffany A Traina, Clifford A Hudis, Ricardo J Marques
IMPORTANCE: Chemotherapy may result in a detrimental effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage breast cancer (EBC). To minimize risk of harm to ovarian function and fertility for patients in this setting, careful considerations should be made. Gonadotropin-releasing hormone agonists (GnRHa) have been suggested as an alternative to prevent the loss of ovarian function due to exposure to cytotoxic agents, but GnRHa use for ovarian protection in EBC patients is not fully resolved...
January 2016: JAMA Oncology
https://www.readbyqxmd.com/read/24082083/hippo-signaling-disruption-and-akt-stimulation-of-ovarian-follicles-for-infertility-treatment
#7
Kazuhiro Kawamura, Yuan Cheng, Nao Suzuki, Masashi Deguchi, Yorino Sato, Seido Takae, Chi-hong Ho, Nanami Kawamura, Midori Tamura, Shu Hashimoto, Yodo Sugishita, Yoshiharu Morimoto, Yoshihiko Hosoi, Nobuhito Yoshioka, Bunpei Ishizuka, Aaron J Hsueh
Primary ovarian insufficiency (POI) and polycystic ovarian syndrome are ovarian diseases causing infertility. Although there is no effective treatment for POI, therapies for polycystic ovarian syndrome include ovarian wedge resection or laser drilling to induce follicle growth. Underlying mechanisms for these disruptive procedures are unclear. Here, we explored the role of the conserved Hippo signaling pathway that serves to maintain optimal size across organs and species. We found that fragmentation of murine ovaries promoted actin polymerization and disrupted ovarian Hippo signaling, leading to increased expression of downstream growth factors, promotion of follicle growth, and the generation of mature oocytes...
October 22, 2013: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/25567618/successful-fertility-preservation-following-ovarian-tissue-vitrification-in-patients-with-primary-ovarian-insufficiency
#8
Nao Suzuki, Nobuhito Yoshioka, Seido Takae, Yodo Sugishita, Midori Tamura, Shu Hashimoto, Yoshiharu Morimoto, Kazuhiro Kawamura
STUDY QUESTION: Is ovarian tissue cryopreservation using vitrification followed by in vitro activation (IVA) of dormant follicles a potential approach for infertility treatment of patients with primary ovarian insufficiency (POI)? SUMMARY ANSWER: Our vitrification approach followed by IVA treatment is a potential infertility therapy for POI patients whose ovaries contain residual follicles. WHAT IS KNOWN ALREADY: Akt (protein kinase B) stimulators [PTEN (phosphatase with TENsin homology deleted in chromosome 10) inhibitor and phosphatidyinositol-3-kinase (PI3 kinase) stimulator] activate dormant primordial follicles in vitro and ovarian fragmentation disrupts the Hippo signaling pathway, leading to the promotion of follicle growth...
March 2015: Human Reproduction
https://www.readbyqxmd.com/read/15919682/premature-ovarian-failure
#9
REVIEW
Deepti Goswami, Gerard S Conway
Premature ovarian failure (POF) causing hypergonadotrophic hypogonadism occurs in 1% of women. In majority of cases the underlying cause is not identified. The known causes include: (a) Genetic aberrations, which could involve the X chromosome or autosomes. A large number of genes have been screened as candidates for causing POF; however, few clear causal mutations have been identified. (b) Autoimmune ovarian damage, as suggested by the observed association of POF with other autoimmune disorders. Anti-ovarian antibodies are reported in POF by several studies, but their specificity and pathogenic role are questionable...
July 2005: Human Reproduction Update
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"